Humacyte’s stock rose 29.6% after Symvess sales more than doubled quarter over quarter, hospital adoption expanded, and management forecast at least a doubling of Q4 sales. The positive reaction also reflects progress toward the dialysis-access filing and the start of a Phase 2a CABG study.
- Q3 Symvess sales were slightly over $1 million, up 151% from Q2 and above the company’s internal goal.
- Hospitals ordering Symvess increased 44%, from 34 at the end of Q2 to 49 at September 30.
- October sales reached $800,000; management expects Q4 sales to at least double Q3 and anticipates at least 20 additional hospitals able to order by year-end.
- The supplemental BLA for ATEV in dialysis access is on track for submission later this month, supported by results from three Phase 3 studies.
- Humacyte has initiated its first Phase 2a CTEV study in CABG and is screening patients.
Community Discussion